Can Wang
Impact in
- Nephrology top 5%
- Gout, Hyperuricemia, Uric Acid
- Infectious Diseases top 10%
- Antifungal resistance and susceptibility
Papers in
-
- COVID-19 epidemiological studies 7
-
- SARS-CoV-2 and COVID-19 Research 7
- SARS-CoV-2 detection and testing 4
- Antifungal resistance and susceptibility 3
- Co-authors
- Wenting MoYanbing ZhaoRichard J. MironShihang ZhengYulan WangJianfei LiangLingling ZhangYufeng Zhang
In The Last Decade
Can Wang
37 papers receiving 991 citations
Peers
Comparison fields: 5 of 117
- Nephrology 118
- Infectious Diseases 203
- Molecular Medicine 43
- Biomedical Engineering 359
- Microbiology 48
Countries citing papers authored by Can Wang
This map shows the geographic impact of Can Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Can Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Can Wang more than expected).
Fields of papers citing papers by Can Wang
This network shows the impact of papers produced by Can Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Can Wang. The network helps show where Can Wang may publish in the future.
Co-authors
The 25 scholars most cited alongside Can Wang, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 4 | |
| 2 | 2024 | 11 | |
| 3 | 2024 | 1 | |
| 4 | 2023 | 3 | |
| 5 | 2023 | 4 | |
| 6 | 2023 | 7 | |
| 7 | 2023 | 6 | |
| 8 | 2022 | 14 | |
| 9 | 2022 | 13 | |
| 10 | 2021 | 0 | |
| 11 | 2021 | 22 | |
| 12 | 2020 | 3 | |
| 13 | 2019 | 9 | |
| 14 | 2017 | 24 | |
| 15 | 2017 | 39 | |
| 16 | 2017 | 113 | |
| 17 | 2015 | 11 | |
| 18 | 2011 | 10 | |
| 19 | Roles of different subtypes of CD4+ T lymphocytes in IFN-α therapy for hepatitis B. | 2010 | 1 |
| 20 | 2007 | 47 |
About Can Wang
Can Wang is a scholar working on Modeling and Simulation, Infectious Diseases, Molecular Medicine, Epidemiology and Microbiology, having authored 40 papers that have together received 1.0k indexed citations. Recurring topics across this work include SARS-CoV-2 and COVID-19 Research (7 papers), COVID-19 epidemiological studies (7 papers), Biosensors and Analytical Detection (5 papers), Respiratory viral infections research (4 papers), SARS-CoV-2 detection and testing (4 papers), Influenza Virus Research Studies (3 papers), Nanoplatforms for cancer theranostics (3 papers) and Antifungal resistance and susceptibility (3 papers). The work is most often cited by research in Nephrology (118 citations), Infectious Diseases (203 citations), Molecular Medicine (43 citations), Biomedical Engineering (359 citations) and Microbiology (48 citations). Can Wang has collaborated with scholars based in China, Hong Kong and Japan. Frequent co-authors include Wenting Mo, Yanbing Zhao, Richard J. Miron, Shihang Zheng, Yulan Wang, Jianfei Liang, Lingling Zhang, Yufeng Zhang, Miusi Shi and Deling Kong. Their work appears in journals such as Scientific Reports, Journal of Clinical Microbiology, Antimicrobial Agents and Chemotherapy, Frontiers of Environmental Science & Engineering and Analytica Chimica Acta.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.